Chronic Obstructive Pulmonary Disease Treatment Market Growth Assesment

Posted by Aman Jaiswar on November 21st, 2019

Transparency Market Research has published a new report on the chronic obstructive pulmonary disease (COPD) treatment market. According to the report, the global chronic obstructive pulmonary disease treatment market was valued at ~US$ 17.4 Mn in 2018. The COPD treatment market is expected to expand at a CAGR of ~5% during the forecast period of 2019 to 2027.

Chronic obstructive pulmonary disease is a group of conditions affecting the lungs, which leads to difficulty in breathing. Chronic bronchitis and emphysema are two major indications included under chronic obstructive pulmonary disease (COPD). Breathlessness is a major characteristic of COPD. In case of emphysema, the alveoli (tiny air sacs) in the lungs are damaged. The walls of the alveoli are stretched, making the lungs bigger, resulting in difficulty in the movement of air. In chronic bronchitis, the bronchial airways (breathing tubes) inside the lungs are inflamed.

Request a PDF Sample of Chronic Obstructive Pulmonary Disease Treatment Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=73763

In terms of drug class, the combination therapy segment of the chronic obstructive pulmonary disease treatment market held a major share of the global COPD treatment market in 2018. It is likely to maintain its dominance in the chronic obstructive pulmonary disease treatment market during the forecast period, owing to its increased efficacy for COPD treatment. Based on distribution channel, the retail pharmacies segment of the COPD treatment market is estimated to account for a major share of the market.

This segment of the chronic obstructive pulmonary disease treatment market is anticipated to expand at a rapid pace during the forecast period, owing to an increase in the number of COPD therapeutics being dispensed through retail pharmacies, and rise in the number of retail pharmacies in developing countries. Chronic obstructive pulmonary disease is characterized by progressive airflow limitation not fully reversible, and is a major cause of morbidity and mortality, worldwide. However, patent expiry of branded products and availability of generic equivalents and alternative treatment options are factors that are expected to hamper the growth of the global COPD treatment market during the forecast period.

Chronic Obstructive Pulmonary Disease Treatment Market: Key Players

Key players are expanding their footprint to strengthen their position in the global chronic obstructive pulmonary disease treatment market. Emerging economies, due to increase in the number of patient population, and rise in tobacco smoking and air population, offer lucrative opportunities to key players to increase their market share. Manufacturers are engaging in new product development, collaborations, acquisitions, and distribution agreements. For instance, in July 2018, Orion Corporation signed a multi-year licensing agreement with Menarini to distribute and commercialize the former’s Easyhaler products. According to the agreement, Menarini would be supplying Orion’s products in Asia Pacific countries such as China, the Philippines, Malaysia, Hong Kong, Indonesia, Vietnam, Thailand, Singapore, South Korea, and Taiwan.

Global Chronic Obstructive Pulmonary Disease Treatment Market: Prominent Regions

North America held a major share of the global chronic obstructive pulmonary disease treatment market. The COPD treatment market in the region is primarily driven by factors such as highly structured healthcare industry and availability of well-defined reimbursement policies from private and public health insurance firms. In addition, extensive research and development to provide advanced and efficient products, and a large number of players in the region, are factors driving the chronic obstructive pulmonary disease treatment market in North America. The chronic obstructive pulmonary disease market in Asia Pacific is estimated to witness significant growth. Asia Pacific is a relatively untapped COPD treatment market as compared to developed regions. Hence, the region offers immense growth opportunities to market players. Factors such as high prevalence of chronic obstructive pulmonary disease, rise in geriatric population, surge in patient population, and growth of the healthcare industry are fueling the expansion of the COPD treatment market in the region.

Europe held the second-largest share of the global chronic obstructive pulmonary disease treatment market in 2018. Well-developed healthcare infrastructure and increase in the number of incidences of chronic obstructive pulmonary disease are driving the COPD treatment market in the region. The chronic obstructive pulmonary disease treatment markets in the Middle East & Africa and Latin America are projected to witness moderate growth in the near future.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving method-ologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of re-search is the key to help enterprises reach right decision.